文献速递乳腺癌

接受新辅助化疗的高危早期乳腺癌患者辅助阿贝西利联合内分泌治疗:monarchE随机临床试验预设分析

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2022-01-01

monarchE试验预设分析纳入2056例接受新辅助化疗的HR阳性、ERBB2阴性、淋巴结阳性高危早期乳腺癌患者,辅助阿贝西利联合内分泌治疗较单用内分泌治疗显著改善无浸润性疾病生存(HR 0.61,95%CI 0.47-0.80)和远处无复发生存(HR 0.61,95%CI 0.46-0.81),2年绝对获益分别为6.6%和6.7%。

要点

  • 新辅助化疗亚组中阿贝西利联合内分泌治疗降低浸润性疾病复发风险(HR 0.61,95%CI 0.47-0.80)。
  • 远处复发风险同样降低(HR 0.61,95%CI 0.46-0.81),2年绝对获益6.7%。
  • 病理肿瘤大小或阳性淋巴结数各亚组获益一致。

核心结论

  • 在接受新辅助化疗的HR阳性、ERBB2阴性、淋巴结阳性高危早期乳腺癌患者中,辅助阿贝西利联合内分泌治疗较单用内分泌治疗在无浸润性疾病生存和远处无复发生存方面显示出有临床意义的改善。

研究设计与样本

  • monarchE为多中心、3期、开放标签随机临床试验,2017年7月至2019年8月从38个国家603个中心招募患者。
  • 纳入HR阳性、ERBB2阴性、淋巴结阳性高危早期乳腺癌患者,按1:1随机接受标准内分泌治疗至少5年联合或不联合阿贝西利(150 mg,每日两次)治疗2年。
  • 本文为预设探索性分析,纳入接受新辅助化疗的2056例患者(占5637例的37%),数据截止2020年7月8日,中位随访19个月(IQR 15.6-23.9个月)。

主要发现

  • 新辅助化疗亚组中,阿贝西利联合内分泌治疗组对比单用内分泌治疗组:无浸润性疾病生存HR 0.61(95%CI 0.47-0.80),2年无浸润性疾病生存率绝对提高6.6%。
  • 新辅助化疗亚组中,阿贝西利联合内分泌治疗组对比单用内分泌治疗组:远处无复发生存HR 0.61(95%CI 0.46-0.81),2年远处无复发生存率绝对提高6.7%。
  • 在病理乳腺肿瘤大小或手术时阳性淋巴结数的各亚组中观察到一致的治疗获益。

局限性

  • 本分析数据来自主要结局分析(395例无浸润性疾病生存事件),中位随访19个月(IQR 15.6-23.9个月),随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients selected to receive neoadjuvant chemotherapy (NAC) are usually those at higher risk of relapse, and there is a need to find better therapeutic options for these patients. OBJECTIVE: To determine the efficacy and safety outcomes for patients with hormone receptor (HR)-positive, ERBB2 (formerly HER2)-, high-risk early breast cancer enrolled in the randomized clinical trial monarchE who received NAC. DESIGN, SETTING, AND PARTICIPANTS: The monarchE randomized clinical trial was a multicenter, phase 3, open-label study that evaluated adjuvant treatment with abemaciclib plus endocrine therapy (ET) compared with ET alone in patients with HR+, ERBB2-, and node-positive early breast cancer who were at high risk of recurrence. Patients were recruited between July 2017 and August 2019 from 603 sites in 38 countries. This subgroup analysis was performed with primary outcome data, with a cutoff date of July 8, 2020. INTERVENTION: Enrolled patients were randomized (1:1) to receive standard of care ET for at least 5 years with or without treatment with abemaciclib (150 mg, twice daily) for 2 years (treatment period) or until criteria were met for discontinuation. MAIN OUTCOMES AND MEASURES: Prior chemotherapy (NAC vs adjuvant vs none) was a stratification factor in monarchE, and and a prespecified exploratory analysis included outcomes in patients who received NAC. The data presented in this article are from the primary outcome analysis (395 invasive disease-free survival [IDFS] events; cutoff date, July 8, 2020; median follow-up 19 months [IQR, 15.6-23.9 months]). Invasive disease-free survival (the primary end point of monarchE) and distant relapse-free survival (DRFS) were evaluated using the Cox proportional hazard model and Kaplan-Meier method. RESULTS: Of the 5637 patients (mean [SD] age, 49.9 [10.6] years; 2046 women [99.5%]; 462 Asian [22.8%], 54 Black [2.7%], and 1473 White participants [70.8%]) enrolled in monarchE, 2056 (37%) received treatment with NAC. In this subgroup, treatment with abemaciclib and ET demonstrated clinically meaningful benefit in IDFS (hazard ratio, 0.61; 95% CI, 0.47-0.80) and DRFS (hazard ratio, 0.61; 95% CI, 0.46-0.81), which corresponded with an absolute improvement of 6.6% in 2-year IDFS rates and 6.7% in 2-year DRFS rates. A consistent treatment benefit was observed across subgroups of pathological breast tumor size or number of positive lymph nodes at surgery. CONCLUSIONS AND RELEVANCE: In the randomized clinical trial monarchE, treatment with adjuvant abemaciclib combined with ET demonstrated a clinically meaningful improvement in IDFS and DRFS for patients with HR+, ERBB2-, node-positive, high-risk early breast cancer who received NAC before trial enrollment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03155997.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Martin M, Hegg R, Kim SB, et al. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 35653145. doi:10.1001/jamaoncol.2022.1488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。